Wednesday, February 23, 2022

10:00 Welcome & Introductions  
Dr. Grace Lee (ACIP Chair)  
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

10:20 Tickborne Encephalitis (TBE) Vaccine  
Introduction  
Dr. Katherine Poehling (ACIP WG Chair)  
Review of considerations for use of TBE vaccine in travelers and laboratorians  
Dr. Susan Hills (CDC/NCEZID)  
Proposed recommendations  
Dr. Susan Hills (CDC/NCEZID)

11:15 Cholera Vaccine
Introduction  
Dr. Pablo Sanchez (ACIP, WG Chair)  
Clinical considerations for use of cholera vaccine in children and adolescents aged 2–17 years  
Dr. Jennifer Collins (CDC/NCEZID)  
Proposed recommendations  
Dr. Jennifer Collins (CDC/NCEZID)

11:50 Break

12:10 Influenza Vaccine
Introduction  
Dr. Keipp Talbott (ACIP, WG Chair)  
Influenza activity update  
Dr. Lisa Grohskopf (CDC/NCIRD)  
Recommending enhanced seasonal influenza vaccines in adults age 65 and older--potential impacts on influenza burden  
Dr. Sinead Morris (CDC/NCIRD)  
Influenza vaccines for older adults  
Dr. Lisa Grohskopf (CDC/NCIRD)

1:10 Hepatitis Vaccine
Introduction  
Dr. Kevin Ault (ACIP, WG Chair)  
PREHEVBRIO for adult HepB vaccination: EtR and GRADE  
Dr. Mark Weng (CDC/NCHHSTP)

1:40 Break

1:55 MMR Vaccine Workgroup
Introduction  
Ms. Lynn Bahta (ACIP, WG Chair)  
MMR safety and immunogenicity  
Dr. Remon Abu-Elyazeed (GSK)

2:25 Public Comment

2:45 VOTE
TBE Vaccine  
Dr. Susan Hills (CDC/NCEZID)  
Cholera Vaccine  
Dr. Jennifer Collins (CDC/NCEZID)

4:00 Adjourn

Thursday, February 24, 2022

10:00 Welcome & Introductions  
Dr. Grace Lee (ACIP Chair)  
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

10:10 Agency Updates
CDC, CMS, FDA, HRSA, HIS, OIDP, NIH

10:25 Pneumococcal Vaccines
Introduction  
Dr. Katherine Poehling (ACIP, WG Chair)  
Epidemiology of pneumococcal disease and pneumococcal vaccine coverage in US children  
Mr. Ryan Gierke (CDC/NCIRD)  
PCV15 Phase 2/3 study results in children  
Dr. Natalie Banniettis (Merck)  
GRADE and EtR for PCV15 use in U.S. children  
Ms. Jennifer Farrar (CDC/NCIRD)  
Summary and next steps  
Dr. Miwako Kobayashi (CDC/NCIRD)

12:15 Adjourn
### Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CMS</td>
<td>Centers for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus disease 2019</td>
</tr>
<tr>
<td>ETR</td>
<td>Evidence to Recommendations Framework</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>GRADE</td>
<td>Grading of Recommendations Assessment, Development and Evaluation</td>
</tr>
<tr>
<td>HRSA</td>
<td>Health Resources and Services Administration</td>
</tr>
<tr>
<td>IHS</td>
<td>Indian Health Service</td>
</tr>
<tr>
<td>NCHHSTP</td>
<td>National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]</td>
</tr>
<tr>
<td>NCIRD</td>
<td>National Center for Immunization &amp; Respiratory Diseases [of CDC/OID]</td>
</tr>
<tr>
<td>NCEZID</td>
<td>National Center for Emerging and Zoonotic Diseases [of CDC/OID]</td>
</tr>
<tr>
<td>NIAID</td>
<td>National Institute of Allergy and Infectious Diseases</td>
</tr>
<tr>
<td>OIDP</td>
<td>Office of Infectious Disease and HIV/AIDS Policy</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>Severe Acute Respiratory Syndrome Coronavirus 2</td>
</tr>
<tr>
<td>WG</td>
<td>Work Group</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>VE</td>
<td>Vaccine Effectiveness</td>
</tr>
</tbody>
</table>